Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...

Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histori ...

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Pfizer will reduce prices on drugs sold to Medicare patients. The Trump administration has made cutting prescription drug prices a priority. Ultimately, the administration aims to have Americans ...